Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteocytes | 3 | 2014 | 18 | 1.120 |
Why?
|
| Femur | 11 | 2015 | 370 | 0.700 |
Why?
|
| Vitallium | 2 | 2011 | 25 | 0.660 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2011 | 181 | 0.620 |
Why?
|
| Ultrasonic Therapy | 4 | 2014 | 24 | 0.620 |
Why?
|
| Prostheses and Implants | 5 | 2014 | 147 | 0.590 |
Why?
|
| Osteogenesis | 8 | 2015 | 104 | 0.570 |
Why?
|
| Transforming Growth Factor beta | 4 | 2014 | 86 | 0.530 |
Why?
|
| Rats | 16 | 2015 | 640 | 0.520 |
Why?
|
| Animals | 21 | 2015 | 3503 | 0.500 |
Why?
|
| Rats, Sprague-Dawley | 15 | 2015 | 320 | 0.480 |
Why?
|
| Bone Morphogenetic Proteins | 3 | 2015 | 68 | 0.460 |
Why?
|
| Titanium | 4 | 2014 | 168 | 0.460 |
Why?
|
| Nickel | 1 | 2014 | 27 | 0.450 |
Why?
|
| Cobalt | 1 | 2014 | 106 | 0.430 |
Why?
|
| Bone Marrow Cells | 3 | 2010 | 53 | 0.400 |
Why?
|
| Bone Regeneration | 5 | 2015 | 69 | 0.380 |
Why?
|
| NFATC Transcription Factors | 1 | 2011 | 10 | 0.360 |
Why?
|
| Calcineurin | 1 | 2011 | 9 | 0.360 |
Why?
|
| Gap Junctions | 1 | 2011 | 12 | 0.350 |
Why?
|
| Cell Communication | 1 | 2011 | 24 | 0.350 |
Why?
|
| Stromal Cells | 2 | 2010 | 33 | 0.350 |
Why?
|
| Signal Transduction | 3 | 2012 | 437 | 0.340 |
Why?
|
| Osteoblasts | 3 | 2015 | 57 | 0.320 |
Why?
|
| Gene Expression | 2 | 2011 | 200 | 0.300 |
Why?
|
| Bone Remodeling | 3 | 2014 | 49 | 0.290 |
Why?
|
| Bone Morphogenetic Protein 2 | 3 | 2014 | 46 | 0.280 |
Why?
|
| Inflammation | 1 | 2009 | 267 | 0.270 |
Why?
|
| Cell Line | 3 | 2014 | 260 | 0.270 |
Why?
|
| Prosthesis Failure | 4 | 2015 | 501 | 0.260 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 76 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2014 | 328 | 0.250 |
Why?
|
| Antibodies | 3 | 2015 | 45 | 0.240 |
Why?
|
| Ultrasonics | 1 | 2005 | 10 | 0.240 |
Why?
|
| Cells, Cultured | 5 | 2011 | 512 | 0.230 |
Why?
|
| Bone Resorption | 4 | 2015 | 82 | 0.220 |
Why?
|
| Bone Marrow | 3 | 2015 | 75 | 0.220 |
Why?
|
| Osseointegration | 2 | 2015 | 67 | 0.210 |
Why?
|
| Osteoporosis | 2 | 2015 | 73 | 0.200 |
Why?
|
| Mice | 4 | 2015 | 1352 | 0.180 |
Why?
|
| Biomarkers | 2 | 2014 | 544 | 0.170 |
Why?
|
| Recombinant Proteins | 4 | 2014 | 178 | 0.150 |
Why?
|
| Cell Differentiation | 2 | 2010 | 132 | 0.140 |
Why?
|
| X-Ray Microtomography | 6 | 2014 | 78 | 0.140 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 72 | 0.140 |
Why?
|
| Models, Animal | 6 | 2014 | 110 | 0.130 |
Why?
|
| Male | 13 | 2014 | 14277 | 0.130 |
Why?
|
| Bone and Bones | 2 | 2015 | 117 | 0.130 |
Why?
|
| Genetic Markers | 2 | 2015 | 33 | 0.130 |
Why?
|
| Materials Testing | 3 | 2012 | 122 | 0.120 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2014 | 6 | 0.110 |
Why?
|
| Molybdenum | 1 | 2014 | 20 | 0.110 |
Why?
|
| Cell Death | 1 | 2014 | 49 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 90 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 52 | 0.110 |
Why?
|
| Bone Matrix | 1 | 2014 | 19 | 0.110 |
Why?
|
| Glycoproteins | 1 | 2014 | 46 | 0.110 |
Why?
|
| Chromium | 1 | 2014 | 85 | 0.110 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 214 | 0.110 |
Why?
|
| Adult Stem Cells | 1 | 2012 | 3 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2012 | 4 | 0.100 |
Why?
|
| Heterocyclic Compounds | 1 | 2012 | 6 | 0.100 |
Why?
|
| Osteolysis | 1 | 2014 | 135 | 0.100 |
Why?
|
| Prosthesis Implantation | 1 | 2012 | 27 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 266 | 0.100 |
Why?
|
| Cell Movement | 1 | 2012 | 79 | 0.100 |
Why?
|
| Fracture Healing | 1 | 2012 | 32 | 0.090 |
Why?
|
| Polyethylene | 1 | 2012 | 120 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 174 | 0.090 |
Why?
|
| Calcineurin Inhibitors | 1 | 2011 | 15 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2011 | 75 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2011 | 118 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2011 | 35 | 0.090 |
Why?
|
| Disease Models, Animal | 4 | 2015 | 577 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 116 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 133 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2009 | 74 | 0.080 |
Why?
|
| Apoptosis | 1 | 2009 | 209 | 0.070 |
Why?
|
| Dactinomycin | 1 | 2007 | 6 | 0.070 |
Why?
|
| Cycloheximide | 1 | 2007 | 7 | 0.070 |
Why?
|
| Growth Differentiation Factor 5 | 1 | 2007 | 7 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 9 | 0.070 |
Why?
|
| Biomimetic Materials | 1 | 2006 | 6 | 0.070 |
Why?
|
| Guided Tissue Regeneration | 1 | 2006 | 11 | 0.070 |
Why?
|
| Extracellular Matrix | 1 | 2006 | 51 | 0.060 |
Why?
|
| Femoral Fractures | 1 | 2006 | 33 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2007 | 168 | 0.060 |
Why?
|
| Genes, jun | 1 | 2005 | 4 | 0.060 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2005 | 5 | 0.060 |
Why?
|
| Osteonectin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Immediate-Early Proteins | 1 | 2005 | 5 | 0.060 |
Why?
|
| Osteopontin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 9 | 0.060 |
Why?
|
| Genes, myc | 1 | 2005 | 9 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 24 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 29 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2005 | 38 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 142 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2005 | 162 | 0.060 |
Why?
|
| Ovariectomy | 2 | 2015 | 26 | 0.050 |
Why?
|
| Regeneration | 2 | 2015 | 18 | 0.050 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2011 | 785 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 268 | 0.050 |
Why?
|
| Random Allocation | 2 | 2012 | 121 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 408 | 0.050 |
Why?
|
| Wnt Proteins | 2 | 2012 | 21 | 0.050 |
Why?
|
| Bone Density | 2 | 2014 | 142 | 0.040 |
Why?
|
| Female | 4 | 2015 | 14734 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2015 | 19 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2015 | 31 | 0.030 |
Why?
|
| Species Specificity | 1 | 2015 | 37 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 96 | 0.030 |
Why?
|
| Diaphyses | 1 | 2014 | 5 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2014 | 25 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 40 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 290 | 0.030 |
Why?
|
| Humans | 2 | 2012 | 25967 | 0.030 |
Why?
|
| Humerus | 1 | 2014 | 106 | 0.030 |
Why?
|
| Periosteum | 1 | 2012 | 4 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2012 | 5 | 0.020 |
Why?
|
| Benzylamines | 1 | 2012 | 10 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2012 | 10 | 0.020 |
Why?
|
| Tensile Strength | 1 | 2012 | 23 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2012 | 17 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 106 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 160 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 181 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2012 | 59 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 84 | 0.020 |
Why?
|
| Tibia | 1 | 2014 | 244 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 173 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 649 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 390 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 616 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 12 | 0.020 |
Why?
|
| Transducers | 1 | 2010 | 10 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2010 | 18 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 19 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 58 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2010 | 40 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 117 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 145 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 143 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 132 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2012 | 633 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 603 | 0.020 |
Why?
|
| Rats, Long-Evans | 1 | 2009 | 11 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2014 | 361 | 0.020 |
Why?
|
| Ossification, Heterotopic | 1 | 2009 | 35 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 648 | 0.020 |
Why?
|
| Time Factors | 1 | 2012 | 1391 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 297 | 0.020 |
Why?
|
| Biomimetics | 1 | 2006 | 6 | 0.020 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2006 | 20 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2006 | 21 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2006 | 31 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2012 | 3399 | 0.010 |
Why?
|